Compare DexCom, Inc. (DXCM) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Jones Lang LaSalle Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B). The key difference: DexCom, Inc. is far larger — about 2.3× Jones Lang LaSalle Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Jones Lang LaSalle Inc for 71 Days on average.
| DXCM | JLL | |
|---|---|---|
Market Cap | $31.86B | $13.95B |
Volume | 3,607,070 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $392.79 |
52-Week Low | $54.84 | $280.16 |
Typical Hold Time | 62 Days | 71 Days |
Enterprise Value | $31.32B | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
JLL trades at $303.14, up 2.18% today, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $26.12B in 2025, and net income improved to $792.10M. Analyst consensus is bullish with a $450.50 price target, though technical indicators show resistance near $307.
Outlook remains positive due to earnings momentum and strategic acquisitions, but risks include market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and ROE of 13.78%, supported by institutional interest and growth in real estate services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
